Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS
 

September 12, 2013

Nuvilex Forms Key Alliance with Industry Leader

Earlier this week, Nuvilex, Inc. (OTCQB – NVLX - $0.15 – Spec Buy) announced it had entered into a contract with Fisher BioServices, Inc., a part of medical services giant Thermo Fisher Scientific, Inc. (NYSE – TMO), for the long-term storage of cells that will be required for future Phase III clinical trials in pancreatic cancer and for studies in other cancers as well. This is a huge deal for Nuvilex and demonstrates how far along the Company is in clinical trial development, which should act as a catalyst to move the stock’s valuation significantly higher. Fisher BioServices is one of the leading companies in critical biological material management and cell and tissue storage with facilities around the world. Over its 28-year history, Fisher BioServices has stored more than 170 million biospecimens, including cells and tissues, as well as their associated data.  Importantly, their facilities are fully GMP compliant – a requirement for an NDA filing.

Nuvilex now owns exclusive rights to a live-cell encapsulation platform technology for all cancers.  This technology has not only successfully completed Phase II trials for advanced, inoperable pancreatic cancer, but also a Phase I/II animal trial for mammary (breast) cancer, and the Company is on the verge of acquiring similar rights to the technology to fight diabetes.  Having a major player like Fisher Bioservices, Inc. as a partner will help ensure that the Phase III trials can be carried out smoothly and thus facilitate the transition into an NDA filing.

The Fisher BioServices facility, located in Rockville, Maryland, is just a few miles from Nuvilex’s International Headquarters, and will be used as one of several cell storage sites around the world holding the cells to be encapsulated that are part of Nuvilex’s pancreatic cancer treatment. Multi-site storage of the critically important cells is Standard Operating Procedure for companies, such as Nuvilex, that are engaged in the use of cells for therapeutic purposes.

The cells to be stored in the Fisher BioServices facilities are the same cells as those used in the previous clinical trials for advanced, inoperable pancreatic cancer that were done with the live-cell encapsulation technology recently acquired by Nuvilex. These cells have the ability to activate the well-known and widely used anticancer drug ifosfamide. They will be maintained in the facility and can be propagated in the event of a loss in the system somewhere else to obtain cells for encapsulation as needed for clinical trials, including those to be employed in the Company's pancreatic cancer treatment.

This partnership is a critical step for Nuvilex and confirms the Company’s status as a well-regarded player in the cancer treatment development segment. On a secondary basis, the close proximity of Fisher BioServices to Nuvilex is a bonus as well. By entering into a relationship with the industry leader, whose parent employs tens of thousands of employees around the world, Nuvilex is making a statement to the industry and its shareholders that the Company is dedicated to reaching its clinical trials objectives as quickly as possible.

For more information, refer to our previous NVLX Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com

Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer
This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since April 2012, Goldman Small Cap Research has been compensated $500 per article by a third party.  This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information.  The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in these articles was derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com